Read More
Read More

In 1998, 51-year-old Marc Lustgarten, Cablevision Vice Chairman, was diagnosed with pancreatic cancer. Colleagues say his larger-than-life presence in a variety of key leadership positions brought out the best in those around him, and he elevated others in all areas of his life. He welcomed even the most daunting challenges as an executive, a husband and as a father; and he faced them in good spirits with his quintessential-New-Yorker sense of humor.

When he began feeling unwell, it took six months for Marc to receive his stage four pancreatic cancer diagnosis, and there were almost no treatment options available. An “orphan disease,” pancreatic cancer was allocated less than half of one percent of the National Cancer Institute’s (NCI) research budget. With no additional funding, few young investigators opted to dedicate their careers to the study of the disease and there was little hope for breakthroughs.


Social Link Listing

Corporate Card

Budget Blinds
National Partner
Learn More
Families Move On
Local Partner
Learn More
Mask Chains by Maggie
Local Partner
Learn More
Frame It for Good
Local Partner
Learn More


Faq Listing

  • What is Classy? plus
  • Is my information secure? plus
  • Why do I have to pay a registration fee? plus
  • How much is the registration fee? plus
At a glance

News From Lustgarten

Thank You Long Island!
Read More
Identifying a Treatment Doctor & Facility
Read More
Jeopardy! The Greatest Of All Time
Read More

Single Post Listing

Grateful Survivor Shares His Journey in New Book

Grateful Survivor Shares His Journey in New Book

Posted On Mar 08,2021
By Vanessa Steil When Joel Evans went to his endocrinologist in 2015 for what he thought would be a routine visit to monitor his diabetes, it turned into anything but. […]

Link Repeater

Square Image Alongside With Content


In 2012, the Lustgarten Foundation established a world-class dedicated laboratory at Cold Spring Harbor Laboratory (CSHL) to focus exclusively on pancreatic cancer research.

In November 2020, with the support of the Lustgarten Foundation, CSHL opened a new 2,200 square-foot organoid facility that is playing a significant role in the PASS-01 clinical trial. The lab is growing and testing organoids for trial participants and will share its work with outside researchers, enabling physicians to make faster, better-informed decisions about which drugs are likely to be most effective.

Progress Promise Newsletter

Community is power. Together we can make an impact.

Join Us and Support Pancreatic Cancer Research

Thanks for signing up!
Tell us a little more about yourself: